PI: Lionel Chow, Cincinnati Children’s Hospital Medical Center (report, grant duration 2011-2013)  Children who develop high-grade glioma (HGG) have a very poor prognosis. New and more effective treatment options are desperately needed to improve patient survival and quality of life. In order to better understand how these tumors grow, we…
PI:  Susan M. Mendrysa, Ph.D., Purdue University Report from first year  (First year, August 2011- September 2012) Funding duration 2011-2013  Medulloblastoma (MB) is the most common malignant brain cancer of childhood.  Although mutations in the p53 tumor suppressor protein are found in the majority of human cancer, p53 mutations are…
Claudia Petritsch, Ph.D., The Regents of the University of California Funding duration 2012-2014 Program summary Studies have shown that a mutant activated form of BRAF, BRAFV600E, and concomitant homozygous deletion of CDKN2A occur in a  subset of pediatric malignant astrocytomas.  Importantly, BRAFV600E transforms CDKN2A-deficient neural progenitor cells and BRAF kinase…
Pamela L. Wolters, Ph.D., Neurobehavioral Program, National Cancer Institute Program duration 2012-2013, one-year Significant cognitive late effects are associated with cranial radiation therapy.  Although treatment regimens have been modified in attempts to reduce neurotoxicity, limited research has focused on therapeutic interventions targeted toward ameliorating or preventing these impairments.  One potential…
Please click on the links below to read grant summaries and abstracts: 2009 A Multi-Institutional Phase II Clinical Trial of a Novel Salvage Induction Chemotherapy Regimen-Gemcitibine Paclitaxel and Oxaliplatin (GemPOx) Followed by a Single High does Chemotherapy (HDC) and Autologous Hematopoietic Progenitor Cell Rescue (AuHPCR) for Patients with Recurrent or…
Page 2 of 2

Thanks to Our Sponsors

CFCLogo2011